Whole-exome sequencing (WES), which analyzes the coding sequence of most annotated genes in the human genome, is an ideal approach to studying fully penetrant autosomal-recessive diseases, and it has been very powerful in identifying disease-causing mutations even when enrollment of affected individuals is limited by reduced survival. In this study, we combined WES with homozygosity analysis of consanguineous pedigrees, which are informative even when a single affected individual is available, to identify genetic mutations responsible for Walker-Warburg syndrome (WWS), a genetically heterogeneous autosomal-recessive disorder that severely affects the development of the brain, eyes, and muscle. Mutations in seven genes are known to cause WWS and explain 50%-60% of cases, but multiple additional genes are expected to be mutated because unexplained cases show suggestive linkage to diverse loci. Using WES in consanguineous WWS-affected families, we found multiple deleterious mutations in GTDC2 (also known as AGO61). GTDC2's predicted role as an uncharacterized glycosyltransferase is consistent with the function of other genes that are known to be mutated in WWS and that are involved in the glycosylation of the transmembrane receptor dystroglycan. Therefore, to explore the role of GTDC2 loss of function during development, we used morpholino-mediated knockdown of its zebrafish ortholog, gtdc2. We found that gtdc2 knockdown in zebrafish replicates all WWS features (hydrocephalus, ocular defects, and muscular dystrophy), strongly suggesting that GTDC2 mutations cause WWS.
Walker-Warburg syndrome (WWS, also known as MDDGA1-7 [MIM 236670, 613150, 253280, 253800, 613153, 613154, and 614643]) is a severe neuromuscular disorder characterized by congenital muscular dystrophy, ocular malformations, smooth appearance of the cortical surface accompanied by neuronal migration defects (cobblestone lissencephaly), and ventricular enlargement (hydrocephalus). 1 [2] [3] [4] [5] but are only identified in 50%-60% of cases. 4, [6] [7] [8] Identification of additional genes mutated in WWS has been hindered by the small size of the available pedigrees, from which DNA is only available from one or two affected individuals. To increase our power to understand the genetic architecture of WWS and to identify mutations in additional genes, we collected a cohort of affected individuals from consanguineous marriages (n ¼ 19; Table S1 , available online). All subjects were enrolled after informed consent was obtained, and research was conducted according to protocols approved by the institutional review board at Boston Children's Hospital. All affected individuals were diagnosed with classic WWS on the basis of the following criteria: (1) brain malformation characterized by cobblestone lissencephaly on neuroimaging, severe hydrocephalus, and cerebellar hypoplasia; (2) the presence of ocular malformations (microphthalmia and macrophthalmia, retinal dysplasia, optic nerve hypoplasia, and anterior chamber defects); and (3) a clinical diagnosis, usually based on severe hypotonia, of congenital muscular dystrophy. 1, 9 Serum creatine kinase and histopathological confirmation of muscular dystrophy were not available in most cases because of the clinical severity and reduced lifespan associated with this condition. We first determined the pattern of homozygosity in the consanguineous pedigrees by hybridizing genomic DNA from the probands and all available family members on whole-genome SNP arrays-Affymetrix 250K StyI or Illumina 610-Quad-at the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University. Genotyping data were analyzed with in-house-developed software for the identification of regions of homozygosity (ROHs) throughout the genome, and genes known to be mutated in WWS were sequenced whenever they were contained in a ROH present only in the affected individual. As we previously reported, 6 homozygous mutations were found in eight families (8 of 19; 42%) (Table S1 ). Homozygosity analysis of the remaining 11 families identified an average percentage of homozygosity of 9.3% (1.3% 5 standard error of the mean), which is larger than the expected 6% for a first-cousin union 10 and suggests increased background consanguinity that could not be captured by the available nuclear pedigrees (Table S1 ). Multiple regions were shared between at least two families, as expected by chance in this type of cohort, but the fact that no region overlapped in more than three families indicates that multiple additional genes remain to be identified. The percentage of homozygosity in the cohort was high but was sufficient to reduce the number of candidate genes to a few hundred or thousand per sample. Therefore, we performed whole-exome sequencing (WES) analysis to study all candidate genes at once. This approach narrowed the number of variants to an average number of five candidates per family (Table S2) . Homozygous mutations in genes known to be involved in WWS were identified in affected individuals in two families ( Figure S1 ); these were a homozygous 1 bp insertion leading to a frameshift change (c.642dup [p.Asp215*]) (NM_006731.2) in FKTN in family 82, a first-cousin union of Hispanic ethnicity from the United States (Table  1 and Figures S1A and S1B), and a homozygous missense change (c.1433A>G [p.His478Arg]) (NM_013382.4) in POMT2 in family 144, a second-cousin union from Sudan (Table 1 and Figures S1C and S1D). The missense change obtained the highest pathogenicity score in two independent pathogenicity prediction algorithms, Polyphen2 14 and SIFT 15 
. Despite being present in a large ROH in the affected individuals, these genes had not been previously sequenced because in each family, a smaller homozygous region with an identical haplotype was present over the gene of interest in one of the parents and was most likely due to a common haplotype in the population. These findings illustrate the power of WES to identify disease-causing mutations in an unbiased manner because all known disease genes can be tested independently.
We then analyzed the variants in the remaining WWSaffected families and identified two independent homozygous changes in glycosyltransferase-like domain-containing 2 (GTDC2), a single-exon gene on the short arm (3p22.1) of chromosome 3 ( Figure 1 ). The first variant was a nonsense change (c.1333C>T [p.Arg445*]) (NM_032806.4) in a male from a Jordanian first-cousin union (family 90, Figure 1C ) and led to a possible early truncation of GTDC2 ( Figure 1G) Figure 1G ). The phenotypes of the two families were undistinguishable from each other and from that of classic WWS cases-they included cobblestone lissencephaly, severe hydrocephalus, severe hypoplasia of the cerebellar vermis, and muscle hypotonia (Table 1 and Figures 1A and 1B) . No muscle biopsy was performed because all affected individuals died within a few days or weeks of birth.
WWS is the most severe of a spectrum of dystroglycanglycosylation disorders affecting the muscle, eyes, and brain. It has variable severity and is commonly defined as muscular-dystrophy dystroglycanopathies (MDDGB1-6 [MIM 613155, 613156, 613151, 613152, 606612, and 608840] and MDDGC1-5 and MDDGC7 [MIM 609308, 613158, 613157, 611588, 607155, and 613818]). 7, 9, 16 We sequenced GTDC2 in a validation cohort of nonconsanguineous cases (n ¼ 52) spanning the dystroglycanopathy phenotypic spectrum to identify additional alleles. We identified an additional nonsense allele in family 86, an Indian family in which two pregnancies were terminated as a result of a diagnosis of ventricular enlargement during gestation. Both fetuses were female and were diagnosed with WWS upon autopsy ( Table 1) . DNA was available from one of the two affected individuals, and sequencing revealed a homozygous GTDC2 mutation (c.590G>A) generating a stop codon at amino acid 197 (p.Trp197*; Figure 1F ). The family displayed a small total amount of homozygosity (1%)-only two regions were larger than 5 cM, and GTDC2 was contained in the largest (7.5 Mb and 5.9 cM) of these regions on chromosome 3 ( Figure 1G )-suggesting that the parents might be distantly related. GTDC2 is an ideal candidate gene for WWS because it is predicted by multiple protein-domain prediction algorithms to contain an uncharacterized glycosyltransferase domain ( Figure 1G ). All genes in which mutations have been identified to date are involved in glycosylation of the transmembrane protein dystroglycan, which must be glycosylated in order to interact with extracellular matrix components such as laminins, and this binding is essential for brain, eye, and muscle integrity.
2,17-19 GTDC2 (which is alternatively called AGO61) is predicted by homology to belong to glycosyltransferase family 61, and, similar to LARGE (another gene involved in dystroglycanopathies), it is also predicted to encode a xylosyltransferase. 20 We studied expression of GTDC2 mRNA in multiple human tissues by using quantitative PCR (qPCR) both during fetal development and in the adult. cDNA samples from postmortem fetal and adult human tissues were obtained commercially (BioChain Institute and Clontech). qPCR was performed with SYBR Green reagents (Applied Biosystems) on an ABI 7500 qPCR platform as previously described 21 with primers hGTDC2_F 5 0 -GCGGAGTCCAGGCTTCAGGCT TTC-3 0 and hGTDC2_R 5 0 -CCGCCGAGAGGTGCATCCT AATG-3 0 and normalizing expression values to beta-actin (ACTB). At both fetal and adult stages, GTDC2 expression was especially high in the brain, muscle, heart, and kidneys (Figure 2A) , which are all variably affected in dystroglycanopathy cases. 6, 22 Brain expression was highest in the cortex and cerebellum (Figure 2A) , and very high expression was also noted in the pancreas ( Figure S2A ). To analyze possible changes in cellular distribution, we analyzed expression of the murine ortholog of GTDC2, Gtdc2, by in situ hybridization (performed at the In Situ Hybridization Core Facility at the University of North Carolina School of Medicine in Chapel Hill, NC) with a probe amplified from an embryonic day (E)12.5 mouse brain cDNA library (a kind gift of Byoung-Il Bae at Boston Children's Hospital) (primers were mGtdc2-forward 5 0 -TTCCCTTACGCTGTCAATCC-3 0 and mGtdc2-reverse 5 0 -TACGTGTTCTCCCCTTGCTC-3 0 ).
We found that Gtdc2 is highly expressed during brain and eye development; it peaks in the cerebral cortex during the last week of gestation in both neuronal progenitors in the ventricular zone and migrating and differentiating neurons but declines around birth, supporting a role for this gene during neuronal development ( Figure 2B ), but we did not observe differential expression in neuronal progenitors or neuronal subtypes.
To test how GTDC2 loss of function would affect brain and muscle development, we used the zebrafish, which has been recently established as an animal model for dystroglycanopathies. [23] [24] [25] [26] The mRNA for the zebrafish ortholog (gtdc2) of GTDC2 was expressed in the zebrafish embryo and larva throughout development; there was especially high expression in the developing brain, eyes, and somites ( Figure 2C and Figure S2B ), consistent with expression of the zebrafish orthologs of other genes mutated in WWS. 27, 28 Zebrafish in situ hybridization was . When these MOs were injected into fertilized zebrafish oocytes, they provided similar results (gtdc2Start at 3-5 ng and gtdc2Splice at 7-10 ng). Therefore, data from only gtdc2Start will be shown. The standard control MO provided by Gene Tools was used as a control at the same concentration used for the experimental MO injections. Injected embryos/larvae and uninjected clutchmate controls were analyzed at 0, 1, 2, and 3 dpf for survival and morphology of the tail, head, and eyes. Developmental defects in gtdc2 morphants were evident from 1 dpf-one quarter of the embryos were severely affected with a very short body, thick and poorly developed tail, and no discernible eyes or head structures. Half of the morphants were mildly affected and were scored on a combination of phenotypes: thick tail, U-shaped somites, reduced mobility inside the chorion, a small head, and underdeveloped eyes, where ventral fusion of the retina was delayed ( Figure 3A) . We asked whether coinjection of the in-vitro-synthesized human GTDC2 mRNA with the gtdc2 MO could improve these phenotypes and found this to be the case ( Figure 3B ). However, almost no rescue effect was observed when we tested the mRNA mutated to include the p.Arg158His allele ( Figure 3C ). The Arg158 residue is highly conserved in GTDC2, and it is located at the beginning of the glycosyltransferase domain; therefore, it is possible that this change might severely impair protein function.
gtdc2 knockdown severely affected survival: 43.4% of embryos died within the first 3 days after injection. However, clutchmates that were uninjected or injected with a control MO displayed survival rates of 98.4% and 89.0%, respectively ( Figure S3A ). Surviving morphants at 3 dpf were shorter than controls and often had a bent tail, impaired motility, smaller eyes in which the retina failed to fuse ventrally, and a domed appearance of the top of the head ( Figures 3D and 3G and Figure S3B ). When pigmentation was blocked at 1 dpf with the addition of 0.003% 1-phenyl 2-thiourea to the water, external analysis of the head revealed extreme ventricular enlargement (hydrocephalus), often accompanied by hemorrhaging ( Figure 3G ), in the most affected larvae (Figure 3E) . Ventral compression and reduction in brain volume were evident upon histological analysis of coronal cryosections stained with DAPI ( Figure 3E ). Disorganization of the retinal epithelium was also observed in a few morphants; there was variable severity in ultrathin plastic-embedded sections stained with 1% toluidine blue and 1% sodium borate ( Figure S3C ) at the Conventional Electron Microscopy Facility at Harvard Medical School. Finally, muscle development was severely disrupted by a loss of both dystrophin and glycosylated dystroglycan from the myosepta, the junction of muscle fibers in which the extracellular matrix is enriched ( Figure 3F) . Disorganization of the muscle fibers was also observed upon histology ( Figure S3D ). These phenotypes (hydrocephalus and retinal and muscle defects) are the hallmarks of WWS and are consistent with the eye, muscle, and brain phenotypes observed in morphants of genes (such as POMT1, POMT2, FKTN, FKRP, and ISPD) previously found to be mutated in WWS. [24] [25] [26] 28 All phenotypes were ameliorated by GTDC2 mRNA injections when embryos were analyzed at 2 and 3 dpf ( Figure 3G and Figure S3E ). In summary, we have combined whole-exome sequencing, homozygosity mapping, and functional analysis in zebrafish to identify and validate GTDC2 mutations as a cause of WWS. In addition, we have reduced the number of candidate variants in other families to a manageable number of five variants per family. This approach will most likely yield additional mutated genes in the future to help unravel the pathways involved in WWS and to determine the role of different glycosyltransferases in brain and muscle development.
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